Compare Lufax Holding Ltd (LU) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs Smith & Nephew plc — how do they compare? Lufax Holding Ltd trades at $0.98 (market cap $982.89M), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 11.3× Lufax Holding Ltd's market cap, and Smith & Nephew plc pays a 2.95% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 13 Days and Smith & Nephew plc for 121 Days on average.
| LU | SNN | |
|---|---|---|
Market Cap | $982.89M | $11.10B |
Volume | 3,323,384 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $3.93 | $37.17 |
52-Week Low | $0.95 | $26.42 |
Typical Hold Time | 13 Days | 121 Days |
Enterprise Value | $58.81B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LU trades at $0.95, down 3.54% on the day, with a bearish technical signal from moving averages but a bullish oscillator reading. The company reported a net loss of $2.10 billion in 2025 on revenue of $23.11 billion, with negative net income margins and ROE. A 10:1 reverse stock split occurred on October 23, 2026, and recent news highlights regulatory challenges and balance sheet strength.
The outlook remains challenged by persistent losses and revenue declines, though deep value is suggested by a P/B of 0.07 and strong parent backing. Risks include regulatory tightening in China and elevated credit costs, but analyst consensus is 69% buy with potential catalysts from capital return events.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
